16.15
-0.06 (-0.37%)
| Penutupan Terdahulu | 16.21 |
| Buka | 16.01 |
| Jumlah Dagangan | 24,416 |
| Purata Dagangan (3B) | 32,170 |
| Modal Pasaran | 5,405,792,256 |
| Harga / Pendapatan (P/E TTM) | 179.44 |
| Harga / Pendapatan (P/E Ke hadapan) | 57.14 |
| Harga / Jualan (P/S) | 10.79 |
| Harga / Buku (P/B) | 15.30 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 |
| Margin Keuntungan | 6.37% |
| Margin Operasi (TTM) | 8.46% |
| EPS Cair (TTM) | 0.090 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 102.33% |
| Nisbah Semasa (MRQ) | 2.78 |
| Aliran Tunai Operasi (OCF TTM) | 43.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 72.81 M |
| Pulangan Atas Aset (ROA TTM) | 5.32% |
| Pulangan Atas Ekuiti (ROE TTM) | 13.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Telix Pharmaceuticals Limited | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| Julat 52 Minggu | ||
| Median | 22.00 (36.22%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 27 Jan 2025 | 22.00 (36.22%) | Beli | 18.01 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |